• Global app revenue approaching $77 billion
• AppSwarm incubates and accelerates emerging talent in crowded market
• Company building on gaming bedrock, adding business resources and cannabis industry networks

In a crowded mobile app market where large global companies dominate the landscape, AppSwarm, Inc. (OTC: SWRM) is working to befriend smaller developers and creative thinkers who hope to elbow their way in and find an audience. The entrepreneur-incubating company has the expertise to identify promising developers who may need some assistance in getting their products to a solid revenue-building stage, as well as the resources needed to help those developers analyze the marketplace, manage the budget and establish direct sales and marketing networks.

Industry analysts expect the mobile app economy to reach a valuation of $77 billion during the coming year (http://dtn.fm/5oAUc), driven largely by the mounting ubiquity of smartphones around the world, together with the growing geographical penetration of 3G and 4G networks and numerous connectivity options such as Bluetooth and Wi-Fi (http://dtn.fm/q1YsS).

AppSwarm tests the emerging apps’ potential for user engagement and retention, capacity to gain viral traction and readiness to monetize their standout features. Many developers launch their products without a ready strategy for gaining users or a realistic model for driving revenue, and they often end up trying to manage the day-to-day funding realities post-launch. AppSwarm’s specialty is in helping to bridge the gap between understanding the apps’ strengths and the audiences using them.

The company’s bedrock foundation is centered in mobile gaming offerings, which fuel a multi-billion dollar industry with a compound annual growth rate of some 31 percent, although AppSwarm has additional revenue streams focused on casino- and movie-themed applications, technical expertise contracts and business utility apps. One example of a business utility app under its banner is a scanner for PDF documents.

The company partners with developers through joint ventures, royalty agreements, marketing partnerships and outright acquisitions. In November, AppSwarm announced that it had finalized discussions with mobile technology developer SinglePoint, Inc. (OTC: SING) to begin producing apps that boost the growing cannabis industry, including a service-based platform for the business-to-business and business-to-consumer markets that is expected to be completed by January 2018. The first app will be a blockchain and bitcoin payment technology marketed under SinglePoint’s SingleSeed subsidiary, and AppSwarm will be responsible for the technical support and application development.

The app is expected to be available in all states where the cannabis industry is legal and the product is feasible, according to the company. The venture calls for an even-split revenue share on all products to be deployed, and AppSwarm expects to report revenues of $6 million to $7 million within the coming year (http://dtn.fm/eV9CL).

During the summer, the company announced its acquisition of Russian development company Shooterboy Entertainment’s Komandir game, which is available for download from the Apple App Store and Google Play. Komandir marks AppSwarm’s foray into virtual reality, a gaming experience that has gained popularity in recent years and is predicted to reach several billion dollars in global revenues within the next four years, with more than $8 billion going toward location-based virtual reality entertainment alone, according to industry analyst Greenlight Insights (http://dtn.fm/1eFW4).

For more information, visit the company’s website at www.App-Swarm.com

Let us hear your thoughts: AppSwarm, Inc. Message Board

• Electric vehicle production increasing demand for lithium
• Chinese firms buying lithium companies
• Chinese investment in Canadian lithium set to grow

China is in the market for lithium, according to the China Economic Review (http://dtn.fm/Spf38). Chinese firms, it says, “Have been on a buying spree for lithium… companies over the past year, signing agreements for future supply of the metals. The string of deals come [sic] as auto companies have announced ambitious plans for electric vehicles in the country.” Recently, the Middle Kingdom overtook the U.S. as the country with the largest number of electric vehicles (EVs) on the road. Already with a strong presence in South America, Chinese buyers appear to be looking to the north, snapping up producers in Canada, home to Standard Lithium Ltd. (TSX.V: SLL) (FRA: S5L) (OTCQX: STLHF). This junior exploration company, based in Vancouver, is out to acquire brownfield, lithium-rich properties in the U.S. It is hoping to unlock value from overlooked U.S. lithium assets by applying both conventional and modern processing technologies. With a brownfield flagship property at Bristol Lake in the Mojave Desert, chances are high that some Chinese buyer may stop and shop.

“China has emerged as a leader in both the supply of—and demand for—electric vehicles,” a McKinsey report proclaims (http://dtn.fm/rb4vK). In 2016, Chinese manufacturers produced approximately 375,000 EVs, which accounted for 43 percent of global production. Suppliers of the lithium-ion batteries that power these vehicles are fast catching up. Chinese players now account for about 25 percent of global sales. Earlier in December 2017, Private Capital Journal reported the acquisition of Canadian producer Lithium X Energy Corp. (TSX.V: LIX) (OTCQX: LIXXF) for about $257 million by a Chinese partnership (http://dtn.fm/JDe5d). One of those partners also purchased a 20 percent stake in London-listed Bacanora Minerals.

China, which has the world’s largest auto market, is undoubtedly in pole position in the EV race. The Chinese government, seeking to cap carbon emissions, plans to phase out vehicles using gasoline and diesel by 2030, after which time only EVs will be sold. Climbing production of EVs is driving up demand for lithium. Battery-grade lithium has been trading at $20,000 a ton on the Chinese spot market, according to Fortune (http://dtn.fm/6iOym). With prices that lofty, Standard Lithium is stepping up its efforts to get the metal out of the ground. Its first project in San Bernardino County, California, at the Bristol Dry Lake has already started to show signs of promise. This past May, Standard Lithium signed an option agreement to conduct lithium exploration and project development under long-standing mineral claims and permits on the Bristol Dry Lake playa held by National Chloride Corporation of America. Test results from a new geophysical survey of the 35,000-acre Bristol Lake site indicate that high concentrations of lithium-bearing brines are present throughout the company’s mineral lease agreement claims.

Standard Lithium announced this past October that (http://dtn.fm/v8W8B) it had entered into a Memorandum of Understanding with TETRA Technologies, Inc., (NYSE: TTI) to secure access to operating and permitted land of approximately 12,100 acres in Bristol Dry Lake and up to 11,840 acres in the adjacent Cadiz Dry Lake of California’s Mojave Desert. With the recent signing of the MOU with TETRA and the option agreement with National Chloride, the actual combined project area in California now covers over 45,000 acres of the two playa. As a result of working with existing operators, a lot of the required infrastructure is already in place. The property, situated approximately 200 kilometers from Las Vegas and 330 kilometers east of the port of Los Angeles, has electric power and water and is crossed in the northwest by a major paved road (Route 66). There is also a Burlington Northern Santa Fe railroad adjacent to the site, with a purpose-built siding and loading spur-line.

Standard Lithium is also exploring for lithium in the Smackover Formation, which extends through Texas, Arkansas and Louisiana. The formation has produced billions of barrels of brines over the last 80 years from an extensive and extremely well-characterized aquifer.

With demand for lithium continuing to climb, Standard Lithium may soon be hearing a knock on the door as Chinese brokers come calling.

For more information, visit the company’s website at www.StandardLithium.com

• DehydraTECH™ is the company’s newly U.S.-patented disruptive drug delivery platform; LXRP CEO Chris Bunka says company is working on more applications for its technology in the treatment of Alzheimer’s disease, Parkinson’s disease, opioid addiction and more
• LXRP has a portfolio of patents issued in both the U.S. and Australia, plus 19 patent applications filed in the U.S. (and internationally using the Patent Cooperation Treaty), as well as national filings in 44 countries
• Company has diverse revenue streams, including out-licensing its technology to third parties with fees ranging from five to 10 percent of gross sales, as well as sales of its hemp oil cannabidiol (CBD) products, ranging from branded protein energy bars to premium teas

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) CEO Chris Bunka said in an audio interview with the Uptick Newswire Podcast (http://dtn.fm/e1KPR) that the company was not only surprised by how quickly it received its patent for DehydraTECH™; it was also surprised by the broadness of the patent awarded for its utilization in other sectors, which it had expected in 2018 and 2019. The company believes that the new patent has locked up the intellectual property (IP) for its next-generation drug delivery system.

“I probably think the company is more undervalued today than it was in the past,” Bunka stated in the interview. “It is potentially world-changing. The potential could deliver aspirin or Ibuprofen better than anyone else. That’s very profound.”

LXRP is a food bioscience company based in Kelowna, British Columbia, Canada, that is a technology disruptor for edible CBD. It markets a high absorption hemp oil formula, protein energy bars, exotic teas and high absorption hemp oil capsules to help the human body absorb CBD. Through potential partnerships, LXRP is now working on applying its technology to improving ingestion of several new products, such as beer, candies, cookies, capsules and pills. It owns international patent rights and has pending patents for its technology changing the way cannabinoids enter the body. Its technology provides increases in intestinal absorption rates, lower dosage size, more rapid delivery to the bloodstream and important taste-masking benefits.

Bunka also said the market does not completely understand the breadth and importance of the patent LXRP received, which also provided patent protection for potential treatment of Alzheimer’s disease, Parkinson’s disease, heart disease, opioid addition and more.

In summary, Bunka said, “The best is absolutely still to come in 2018, and I think it is going to make 2017 look boring in comparison.”

For more information, visit the company’s website at www.LexariaBioscience.com

Let us hear your thoughts: Lexaria Bioscience Corp. Message Board

• If Visa and MasterCard (or others) choose to participate in the marijuana industry in the future, REFG plans to offer quick, full spectrum payment processing
• REFG’s StateSourced payment gateway is Financial Crimes Enforcement Network (FinCEN) compliant
• Medical marijuana sales will grow to $13.3 billion by 2020, and adult recreational marijuana sales are expected to reach $11.2 billion by 2020, according to Forbes

Medical Cannabis Payment Solutions (OTC: REFG) is ready for the future with a seamless transition in the event that Visa or MasterCard (or others) choose to participate in the marijuana industry. In the event of a transition, full spectrum payment processing would be readily available.

REFG provides dispensaries and related businesses with a proprietary merchant processing system designed to serve the needs of state-legalized cannabis markets. The company offers exclusive and proprietary card processing services not otherwise available through most financial institutions. The goal is to offer simple, compliant and secure payment solutions. These solutions apply to the entire cannabis industry — not just medical marijuana retailers. A growing number of marijuana dispensaries and other businesses elect not to participate in a cash-only transaction environment.

REFG is a first-tier merchant processing cannabis industry pioneer. It offers a state-of-the-art system that tracks sales and tax collection. The mission of REFG is to provide end-to-end management, across multiple management systems, to solve the fragmentation problem of medicinal marijuana operations by identifying tools that are important to them.

Offering another processing feature, the company recently announced its partnership agreement with First Bitcoin Capital Corporation (OTC: BITCF) (http://dtn.fm/8xTq6). The agreement will enable marijuana facilities and their consumer clients to conduct payment processing with StateSourced debit cards, in addition to prominent cryptocurrencies such as $Weed and bitcoin. The additional option is available to both dispensaries and consumers, per company reports.

Forbes reports that sales of medical marijuana will reach $13.3 billion by 2020, and adult recreational volume is expected to hit $11.2 billion by 2020 (http://dtn.fm/j3GM5).

For more information, visit the company’s website at www.REFG.co

Let us hear your thoughts: Medical Cannabis Payment Solutions Message Board

• Neuenergy is a chewable and revolutionary energy tablet powered by blueberries and anti-oxidants with no sugar or calories
• NeutriSci International names Glen Rehman as new CEO
• Company sees new opportunities for its product in the cannabinoid field, as well as new strategic partnerships

NeutriSci International, Inc. (OTCQB: NRXCF) (TSX.V: NU) (FRANKFURT: IN9) recently announced that it has raised $499,999.95 in a non-brokered private placement (http://dtn.fm/w5XAP), with the proceeds to be used for marketing and advertising of Neuenergy®, its branded blueberry-powered energy chewable tablet (http://dtn.fm/dKJm7). Funds will also go to the company for general corporate purposes.

In addition, the company announced that previous president Glen Rehman has been named CEO.

“This latest round of investment provides us with the opportunity to move forward with strategic new partnerships, as well as our existing ones,” Rehman stated in a news release. “We have built a solid foundation and are very excited about the opportunities that lie ahead of us as we continue to grow our sales of neuenergy, and expand into new opportunities for our product in the cannabinoid industry.”

The private placement consisted of 5,555,555 units of the company at a price of $0.09 per unit. A unit consists of one common share of the company and a purchase warrant for one-half of one common share. Each full warrant entitles the holder to acquire an additional common share at a price of $0.15 per share until June 6, 2019.

Related to the private placement, the company said it paid $31,136 in cash commissions and issued 345,956 finder’s warrants. Each of those warrants entitles the holder to acquire one common share, at a price of $0.15 per share, until June 6, 2019. All securities issued in conjunction with the placement are subject to a hold period that expires on April 7, 2018.

NeutriSci International is a Vancouver-based company that specializes in the production and formulation of nutraceutical products, with its primary focus being its Neuenergy brand natural energy and focus supplement featuring the beneficial effects of blueberries.

For more information, visit the company’s website at www.NeutriSci.com

• Company has drawn more than 450 million players to its portfolio of 300+ mobile games, with player life time values (LTVs) exceeding the cost of player acquisition on certain titles
• TAPM schedules launch of three new full-featured titles in first two quarters of 2018
• By 2020, mobile gaming market is expected to account for more than half of the total games market, which hit an estimated $108.9 billion this year

Tapinator, Inc. (OTCQB: TAPM) has been successfully growing within the surging mobile games market through its introduction of both licensed and original IP across its portfolio of 300+ games, which have attracted more than 450 million players. One such license is the ROCKY™ mobile game, which the company developed in conjunction with MGM studios. Revenues are generated by consumer app store transactions and branded advertisements.

TAPM is a New York City-based company that builds mobile games for the Apple iOS, Google Play, and Amazon App Store platforms. Its team of developers and marketers uses a proprietary and profit-driven set of processes focused on gaming category, player retention and projected profitability. It is currently experimenting with both virtual and augmented reality as these newer markets begin to take hold.

The opportunities for growth within the mobile gaming market are immense, with Newzoo Research’s ‘Global Games Market Report’ projecting that mobile games will account for more than half of the total global market by 2020 (http://dtn.fm/vFM24). The total gaming market was projected to reach $108.9 billion this year, Newzoo reported. It also estimated that mobile gaming reached $36.9 billion in 2016 (http://dtn.fm/NnQ3i).

What makes TAPM unique is that it focuses on a quantitive approach to generating shareholder value, instead of beginning the game development process with an emphasis on creative alone. Ilya Nikolayev, Tapinator’s founder and CEO, said that TAPM prioritizes games with higher player retention and projected profitability, keeping an eye toward the metrics that show a game can profitably acquire new players. The company applies a pragmatic, profit-oriented strategy in order to ensure that its games are successful in attracting players, and it looks to create series of games from its most successful projects.

Additional keys to Tapinator’s success are rapid development and a commitment to constant improvement of its more successful titles. TAPM has also developed a marketing ecosystem that allows the company to cross-promote its large player base from older titles to its newer game launches. Tapinator uses this proprietary player base to acquire between 350,000 and 400,000 new player downloads daily with no spending on external marketing, Nikolayev said in an interview with Forbes (http://dtn.fm/TcAd1).

For more information, visit the company’s website at www.Tapinator.com

Let us hear your thoughts: Tapinator, Inc. Message Board

• Filing for IGC-506 anticipated to be completed in the U.S. in 2019, expanding the company’s patent portfolio; company is looking at pre-clinical trials for three of its combination drugs, possibly creating enhanced valuation
• IGC has pre-clinical trial scheduled in 2018 for IGC-AD1, a combination-therapy drug designed to treat Alzheimer’s
• IGC-506 is a combination therapy developed from cannabis extracts and other compounds that’s designed to treat multiple types of eating disorders in humans and animals

India Globalization Capital, Inc. (NYSE American: IGC) (FRA: IGS1) anticipates a Patent Cooperation Treaty (“PCT”) filing application by February 28, 2018, for IGC-506, which is designed for the treatment of multiple types of eating disorders in humans, as well as animals in the veterinary market. The company anticipates a U.S. and national filing by August 28, 2019, the company announced (http://dtn.fm/MsLB4). A PCT filing is an international patent filing effective in a number of foreign countries (http://dtn.fm/UrSh0).

The company has a number of provisional patent filings, either already made or anticipated in the future, which could raise its valuation. It already has three products, scheduled for pre-clinical trials, featuring provisional filings for patents. These include IGC-501, a cream/patch for the treatment of neuropathic pain; IGC-502, a veterinary market product for the treatment of seizures; and IGC-504 for the treatment of eating disorders in adult humans as well as for the veterinary market. In 2018, IGC anticipates a pre-clinical trial for IGC-ADI, which is designed to treat Alzheimer’s disease.

IGC is a Maryland-based company engaged in the development of cannabis-based combination therapies to treat Alzheimer’s, several endpoints of Parkinson’s, pain, nausea, eating disorders and epilepsy in dogs and cats. It has two lines of businesses. The first, legacy infrastructure, consists of heavy equipment rental, commodities trading and real estate management. The other is canna-pharmaceutical.

IGC-506 is a combination therapy drug, developed from cannabis-extracts and other compounds, designed to treat multiple types of eating disorders. Cannabinoids are chemical compounds that exert a range of effects on the body. The non-psychoactive phytocannabinoid, cannabidiol (CBD), influences many pathways in humans, as well as cats and dogs, and may be used to provide relief for numerous symptoms ranging from pain to eating disorders.

For more information, visit the company’s website at www.IGCInc.us

• Multifaceted international company, first and only to offer hemp-infused skin care products in China
• Now set to spin off new subsidiaries
• Shareholders likely to benefit from value-add transaction

In business for nearly two decades, ChineseInvestors.com (OTCQB: CIIX) began as a specialized investment services company providing real-time commentary, analysis and education-related services in the Chinese language. While building recurring revenues through its unique 100,000+ user base, CIIX maintained a long term vision for value-add opportunities. In 2016, the company identified one of the fastest growing markets in the world and entered the explosive new medical CBD market. Targeting the nearly two billion Chinese-speaking people worldwide, ChineseInvestors.com launched into online sales of CBD products and continued to expand its core investor education business, adding a daily video telecast on cryptocurrencies aimed at Chinese speakers.

Initially, forays into the Chinese CBD market focused on global online sales of oils through subsidiary ChineseCBDoil.com. As CIIX gained traction and established a significant footprint in the global CBD market, it then opened a huge untapped market by becoming the first and only known company to offer hemp-infused skin care products in China. The company retails its hemp oil-based cannabidiol (CBD) products on Alibaba and Amazon under the “OptHemp” brand through its wholly-owned subsidiaries, CBD Biotechnology Co. Ltd. and ChineseHempOil.com, Inc.

CIIX’s CBD endeavors have proved so successful that the company just announced plans to spin off its wholly-owned foreign enterprise, CBD Biotechnology Co. Ltd., and its wholly-owned subsidiary, ChineseHempOil.com, Inc. in order to transition the subsidiary from a private startup to a successful public company (http://dtn.fm/m4SEE). Spinning off these entities will allow CIIX to focus on its cryptocurrency division and core financial education business.

ChineseInvestor.com CEO Warren Wang, in a news release, said “We are excited to announce our intention to spin off CBD Biotechnology and ChineseHempOil.com, Inc. as we believe the existing business lines and the new acquisitions in China, secured by CEO Summer Yun, will allow these entities to continue to grow in their respective markets, while bringing new value to the company’s existing shareholders. The details about the value to the company’s existing shareholders will be announced in the coming weeks.”

CIIX has managed to incubate a high growth company and has intentions of listing the shares of the subsidiary’s common stock for trading on the OTCQB. This initiative should bode exceptionally well for existing shareholders as the realized value of the transaction becomes more apparent. CIIX will now return focus to its core financial education business and its new cryptocurrency division. With its track record of identifying and seizing upon growth opportunities, it wouldn’t be surprising to see CIIX repeat another successful spinoff.

For more information, visit the company’s website at www.ChineseInvestors.com

Let us hear your thoughts: ChineseInvestors.com, Inc. Message Board

• Recreational and medical marijuana market in U.S. estimated to reach $37 billion by 2024
• Need for payment processing solutions increases as cannabis continues march toward legalization
• Cryptocurrency presents a payment option, along with comprehensive card processing solutions

Medical Cannabis Payment Solutions (OTC: REFG), the industry’s leading end-to-end payment processing solution for the legal marijuana industry, gives cannabis retailers and consumers different payment options besides bringing hard cash to the table.

The company’s unique StateSourced proprietary system offers one of the first and only comprehensive card processing operations to serve state-sanctioned marijuana industries. StateSourced is not a prepaid or gift card, which is an important distinction to merchants and clients alike since financial institutions continue to avoid the legal marijuana sector. Federal law still considers marijuana illegal under the Controlled Substances Act, although 29 states and the District of Columbia have legalized the plant’s use in one form or another.

Medical Cannabis Payment Solutions emphasizes that its debit card can only be used to purchase cannabis-related products from state-sanctioned vendors, which means it must be used for payment within a state where marijuana is legal. The company’s card includes a state-of-the-art system that tracks sales and tax collection, giving businesses a distinct advantage when it comes to client management and meeting regulatory requirements (http://dtn.fm/nfE84).

In another first, the company is collaborating with First Bitcoin Capital Corporation to integrate First Bitcoin’s cryptocurrency ($Weed) with Medical Cannabis Payment Solutions’ StateSourced payment gateway. State-licensed marijuana dispensaries around the country will have the option of accepting StateSourced cards and approved cryptocurrencies, such as Bitcoin and Weedcoin, which frees consumers up from carrying cash to make purchases (http://dtn.fm/XkOC5).

Medical Cannabis Payment Solutions CEO Jeremy Roberts said in a recent interview with NetworkNewsAudio, a service of NetworkNewsWire, that the company’s new website (www.REFG.co) allows consumers to apply online for a StateSourced card.

“We’ll do a short due diligence period as required by law, and then we’ll be able to set up processing for them,” Roberts said in the interview, adding that, once the account is set up, using it is easy, accessible and solves the headache of purchasing product from legal businesses that, until now, have been forced to operate on a cash-only basis.

Numerous industry reports state that the recreational and medical marijuana industries will continue their upward trajectory as the highly-regulated plant becomes more accessible through legalization. A report by Statista shows that the estimated retail sales of medical marijuana in the United States will reach nearly $7 billion by 2021 (http://dtn.fm/8aTvw), but that figure pales somewhat next to the combined market that includes recreational marijuana. The consumer market for both sectors of the marijuana industry is expected to eclipse $26 billion by 2021 (http://dtn.fm/Actt1), with significant increases expected over the following three years, when the market size is expected to reach $37 billion.

Medical Cannabis Payment Solutions provides hand-crafted, secure financial solutions for the cannabis industry. The company’s commitment to providing customers, dispensaries and related businesses working in the state-legalized cannabis markets with real, working solutions to a frustrating problem is front and center on its new website.

For more information, visit the company’s website at www.REFG.co

Let us hear your thoughts: Medical Cannabis Payment Solutions Message Board

• CIIX board has agreed, by the end of February 2018, to spin off its consumer products division in the U.S. and China, including its hemp oil assets and its new wholesale alcohol distribution division
• CIIX plans to register ChineseHempOil.com, Inc. as a separate publicly-traded company to be listed on the OTCQB
• Warren Wang, CEO of CIIX, said that the move will allow these businesses to grow in their respective markets

ChineseInvestors.com, Inc. (OTCQB: CIIX) is spinning off its wholly-owned foreign entity, CBD Biotechnology Co., Ltd., and its wholly-owned subsidiary, ChineseHempOil.com, Inc., to allow itself to focus on its new cryptocurrency division and its core financial education division, the company announced (http://dtn.fm/lN10M).

In a news release, Warren Wang, CEO of CIIX, said, “We are excited to announce our intention to spin off CBD Biotechnology and ChineseHempOil.com, Inc., as we believe the existing business lines and the new acquisitions in China, secured by CEO (of CBD Biotechnology Co., Ltd.) Summer Yun, will allow these entities to continue to grow in their respective markets, while bringing new value to the company’s existing shareholders. The details about the value to the company’s existing shareholders will be announced in the coming weeks.”

CIIX is a diverse educational and consulting company for the Chinese-speaking community in China and the U.S. Subscriptions and investor relations have provided the company with key revenue streams. In addition to educational coverage of bitcoin and other cryptocurrencies, CIIX has a core financial education and consulting business.

It has committed itself to cryptocurrency education and active involvement. It broadcasts a daily video from the NYSE titled ‘Bitcoin MultiMillionaire’. It has also recently reached agreement to host a bitcoin ATM in the lobby of its headquarters in San Gabriel, California. The unit it hosts has been installed by Blockchain BTM LLC. The start of futures trading in bitcoin on the Chicago Mercantile Exchange by CBOE Global Markets, Inc., according to a MarketWatch report (http://dtn.fm/r99pL), may attract even more investors and simplify the process of gaining exposure to bitcoin for both retail and institutional investors. CNN reported that the new futures trading has spurred even more interest from the investor community (http://dtn.fm/Dcs7N).

Yun added, “The decision to expand CBD Biotechnology’s Chinese Consumer Division to include baijiu liquor sales is part of a strategic plan to increase revenues in the coming year. By aligning with China GuiZhou HanTai Wine, Inc., CBD Biotechnology has partnered with a proven leader in the Chinese baijiu market.” Baijiu is a Chinese alcoholic beverage made from grain.

“In addition to distribution rights, the agreement between CBD Biotechnology and China GuiZhou HanTai Wine, Inc., affords CBD Biotechnology the opportunity to launch its own brand of baijiu in the future,” Yun added. CBD Biotechnology has a huge opportunity to gain significant market share as ultra-premium baijiu is expected to jump 16% in volume per year over the next five years as the number of high-wage earners in China soars.

As part of the transaction, CBD Biotechnology Co., Ltd. will acquire a Chinese Wholesale Alcohol License, expanding its Chinese consumer division to include the distribution of baijiu. On November 7, 2017, the Shanghai Wine Monopoly Bureau issued the license for a three-year term to CBD Biotechnology.

CBD Biotechnology has also entered an agreement with China GuiZhou HanTai Wine, Inc., to distribute its brand of baijiu, Yantai 1985, and partnered with Jinri Toutiao (translation: Today’s Headlines), a popular Chinese mobile app. Jinri Toutiao is the first broad news aggregator in China, featuring real time news, games, movies and music. It has more than 600 million registered users. It will be used for sales and marketing by CBD Biotechnology.

For more information, visit the company’s website at www.ChineseInvestors.com

Let us hear your thoughts: ChineseInvestors.com, Inc. Message Board